Medicare spending on drugs with accelerated approval

JAMA Network

What The Study Did: This study found that Medicare spending from 2015 through 2019 on drugs with an accelerated approval indication doubled from $4.7 billion to $9.1 billion, with most of this growth among Part B drugs.

Authors: Benjamin N. Rome, M.D., M.P.H., of Brigham and Women’s Hospital in Boston, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link


/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.